ATAlejandra Tapia-Castillo

Alejandra Tapia-Castillo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alejandra Tapia-Castillo has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Non-classic apparent mineralocorticoid excess syndrome: current evidence and future challenges

    by Cristian A Carvajal, Alejandra Tapia-Castillo, Thomas Uslar, Anand Vaidya, Jorge A Pérez, René Baudrand, Carlos E Fardella

    Hypertension affects over 1.3 billion people worldwide and is the leading modifiable cause of cardiovascular morbidity and mortality. Approximately one-third of individuals with hypertension exhibit a low-renin phenotype, a clinically heterogeneous subgroup in which the underlying etiology remains uncharacterized in most cases. Among its mechanistic contributors, non-classic apparent mineralocorticoid excess (NC-AME) represents a prevalent and under recognized cause of cortisol-mediated mineralocorticoid receptor over activation that has, to date, lacked a formal clinical definition, standardized diagnostic criteria, or evidence-based therapeutic framework. This review addresses that gap. NC-AME is formally defined as a syndrome of partial 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) insufficiency occurring in the absence of biallelic human HSD11B2 variants, biochemically characterized by an elevated cortisol-to-cortisone (F/E) ratio and low cortisone concentration, and typically associated with low plasma renin, normal-to-low aldosterone, and elevated blood pressure. The review consolidates evidence across 3 mechanistic domains, genetic and epigenetic dysregulation of HSD11B2 gene, endogenous and exogenous enzyme inhibition, and patient-specific alterations (ie, age, sex, renal function), and proposes a structured LC-MS/MS-based diagnostic algorithm, and a resource-adapted diagnostic approach. Mineralocorticoid receptor antagonists are endorsed as mechanism-directed first-line therapy, with blood pressure and renin normalization as co-primary treatment targets. Acquired and reversible causes are classified separately to guide clinical management. A research agenda is advanced to drive threshold standardization, multicenter validation, and integration of NC-AME into hypertension guidelines across endocrinology, cardiology, and nephrology.

  • Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study

    by Thomas Uslar, Benjamín Sanfuentes, Roberto Olmos, Alberth Burnier, Pauline Böhm, Francisco J. Guarda, Álvaro Huete, Nicolás Mertens, Cecilia Besa, Marcelo Andía, et al.


  • Open Access

    Novel nonsteroidal inhibitors of the human 11-beta hydroxysteroid dehydrogenase type 1 enzyme for the treatment of obesity and metabolic syndrome

    by Pablo González, Cristian A. Carvajal, Alejandra Tapia-Castillo, Gonzalo Recabarren, Benjamín Diethelm, Eduardo Riquelme, Mauricio A. García, Andrea Vecchiola, Fidel A. Allende, Jorge A. Pérez, et al.

    Nontumoral cortisol dysregulation in obese individuals is associated with many facets of metabolic syndrome, including central adiposity, diabetes mellitus (T2DM), dyslipidemia, and hypertension. Glucocorticoid availability and function at the cell/tissue level are classically regulated by 11-beta hydroxysteroid dehydrogenase type (11β-HSD) enzymes. The 11β-HSD1 enzyme is expressed primarily in the liver and adipose tissue (AT) where cortisone in converted into its active form, cortisol. 11β-HSD1 expression in AT promotes adipocyte proliferation and hypertension, leading to the development of abdominal obesity and comorbidities. The 11β-HSD1 enzyme is a key therapeutic target for modulating obesity and associated metabolic disorders.In response to this need, our research aimed to design and characterize a family of nonsteroidal compounds displaying specific and selective inhibition of the 11β-HSD1 enzyme. For this purpose, we designed, synthetized, and characterized a family of adamantyloxadiazole compounds to selectively inhibit the human 11β-HSD1 enzyme that are henceforth designated sequentially from A to N (14 compounds). Our newly synthesized compounds were designed in silico and synthesized via retrosynthesis. We tested the following properties of our novel compounds: (1) their biopharmaceutical properties, (2) their inhibitory potency (IC50) over 11β-HSD1 reductase activity in cell-free assays, and (3) their relative inhibitory potency and IC50 in human adipocytes.Biopharmaceutical characterization of the compounds revealed high transcellular permeability and no interaction with P-glycoprotein, a known efflux pump that decreases oral systemic and central exposure, for Compounds J and L . In vitro studies of the inhibition of the 11β-HSD1 enzyme via cell-free and microsome-based assays indicated significant inhibitory potency, with optimal specificity and selectivity observed at the nanomolar level, highlighting both the IC50 values of Compound J (11,8 nM) and Compound L (3,9 nM), which also preserve 11b-HSD oxidase activities (> 90%). In human adipocytes, 1 µM Compounds E , J and L demonstrated a high potency of 11β-HSD1 inhibition, near 40–60%, compared to 1 µM inhibitor carbenoxolone, which showed approximately a 90% inhibition.The preclinical evaluation of these adamantyloxadiazole derivatives revealed their potential as effective inhibitors of the 11β-HSD1 enzyme, with Compounds E , J and L showing particularly relevant performance in vitro . These findings support the progression of in vivo studies to further explore their therapeutic potential in treating obesity and associated metabolic disorders.

  • Primary Aldosteronism in a Hispanic Cohort: Responses to Mineralocorticoid Receptor Antagonism and Remission in a Case

    by Alejandra Tapia-Castillo, Andrea Vecchiola, Paola Quiñones, René Baudrand, Thomas Uslar, José Delgado, Cristian A Carvajal, Carlos E Fardella

    BACKGROUND: Primary aldosteronism (PA) is the main cause of secondary arterial hypertension. In this study, we present the medical treatment of Hispanic patients with PA followed for up to 5 years, highlighting the complete cure with pharmacological treatment in one of our patients. METHODS: We studied 32 PA patients, followed every 6 months after starting MRA. A clinical response was the normalization of blood pressure (BP) in the absence of other antihypertensive drugs. The biochemical response was considered with normalization of potassium and renin. Responses to treatment were compared using the defined daily dose (DDD). The effect of MRA was evaluated in vitro. The HAC15 cells were cultured and stimulated with aldosterone and spironolactone for 24–72 h, and the apoptotic cell death was measured. RESULTS: At 12 months posttreatment with MRA, 68% of the patients had a total clinical response, and 67% had a total biochemical response. Response to MRA treatment reduced DDD by an average of 74%. Additionally, we observed one PA patient treated with spironolactone after 3 years, he presented a pharmacological cure with normalization of aldosterone and renin without treatment with spironolactone. The in vitro study shows that spironolactone increased early apoptosis by 60% and late apoptosis by 50%. CONCLUSIONS: These results suggest the importance of timely diagnosis of PA and specific treatment with MRA, especially in patients with a poor response to treatment. Moreover, remission of PA may occur in some patients after spironolactone treatment due to its suggestive role as an apoptotic agent.


  • Influence of estradiol deficiency on the mineralocorticoid receptor response in postmenopausal women: a cross-sectional study

    by Alejandra Martínez-García, Jorge A. Pérez, Alejandra Tapia-Castillo, María P. Hernández, Marlin Solórzano, Pablo Carrión, Carlos E. Fardella, Cristian A. Carvajal

    Premenopausal women (PreM) have a cardioprotective advantage over postmenopausal women (PostM) due to estrogen. The interaction of estrogen with the mineralocorticoid receptor (MR) pathway remains unexplored. This study aimed to identify changes in aldosterone, renin and sexual steroid levels and MR surrogate biomarkers in PostM that may explain changes in blood pressure and renal damage. A cross-sectional study was carried out with 47 normotensive and hypertensive Chilean women distributed between PreM and PostM. Clinical, anthropometric and biochemical parameters, including aldosterone, plasma renin activity (PRA) and surrogate markers of MR activity, were assessed. PostM had greater systolic blood pressure (SBP) (p < 0.001) than PreM. A negative correlation was observed between estradiol and fractional excretion of potassium (FEK) (ρ = -0.29; p = 0.023), adjusted for age and SBP. Compared with hypertensive PreM, hypertensive PostM (PostM-HT) showed reduced PRA (p = 0.045) and greater FEK (p = 0.04). Normotensive PostM (Post-NT) exhibited greater SBP (p = 0.03), neutrophil gelatinase-associated lipocalin (NGAL) levels (p = 0.04) and FEK (p = 0.03) than normotensive PreM. Our results suggest enhanced MR sensitivity not only in PostM-HT, as evidenced by lower PRA and elevated FEK, but also in PostM-NT, who exhibited greater FEK and NGAL levels, surrogate markers of MR activation. These results support a novel role of MR activation and cardiovascular risk in PostM women.


  • Open Access

    Letter to the Editor From Tapia-Castillo et al.: “Considerations About the Indirect Role of Low Cortisone in Subjects With Normal Cortisol to Cortisone Ratio”

    by Alejandra Tapia-Castillo, Cristian A Carvajal, Carlos E Fardella

    We appreciate the comments of Armanini et al [1] concerning our recent article published in the Journal of the Endocrine Society [2]. We would like to clar


  • Open Access

    Adipose Tissue Dysfunction and the Role of Adipocyte-Derived Extracellular Vesicles in Obesity and Metabolic Syndrome

    by Alejandra Sandoval-Bórquez, Pablo Carrión, María Paz Hernández, Jorge A Pérez, Alejandra Tapia-Castillo, Andrea Vecchiola, Carlos E Fardella, Cristian A Carvajal

    Obesity is a major public health issue that is associated with metabolic diseases including diabetes mellitus type 2 and metabolic syndrome. This pathology leads to detrimental cardiovascular health and secondary effects, such as lipotoxicity, inflammation, and oxidative stress. Recently, extracellular vesicles (EVs) have been highlighted as novel players participating in human physiology and pathophysiology. In obesity, adipose tissue is related to the active shedding of adipocyte-derived extracellular vesicles (AdEVs). The current review explores and highlights the role of AdEVs and their cargo in obesity and metabolic syndrome. AdEVs are proposed to play an important role in obesity and its comorbidities. AdEVs are biological nanoparticles mainly shed by visceral and subcutaneous adipose tissue, acting in physiological and pathophysiological conditions, and also carrying different cargo biomolecules, such as RNA, microRNA (miRNA), proteins, and lipids, among others. RNA and miRNA have local and systemic effects affecting gene expression in target cell types via paracrine and endocrine actions. State of the art analyses identified some miRNAs, such as miR-222, miR-23b, miR-4429, miR-148b, and miR-4269, that could potentially affect cell pathways involved in obesity-related comorbidities, such as chronic inflammation and fibrosis. Similarly, AdEVs-proteins (RBP4, perilipin-A, FABP, mimecan, TGFBI) and AdEVs-lipids (sphingolipids) have been linked to the obesity pathophysiology. The current knowledge about AdEVs along with further research would support and reveal novel pathways, potential biomarkers, and therapeutic options in obesity.


  • Open Access

    Low Cortisone as a Novel Predictor of the Low-Renin Phenotype

    by Alejandra Tapia-Castillo, Cristian A Carvajal, Jorge A Pérez, Alejandra Sandoval, Fidel Allende, Sandra Solari, Carlos E Fardella

    A large proportion of patients with low-renin hypertension (LRH) correspond to primary aldosteronism (PA). However, some of these subjects have low to normal aldosterone. Since low renin is driven by excessive mineralocorticoids or glucocorticoids acting on mineralocorticoid receptors (MRs), we hypothesize that a low-cortisone condition, associated classically with 11βHSD2 deficiency, is a proxy of chronic MR activation by cortisol, which can also lead to low renin, elevated blood pressure, and renal and vascular alterations. Objective To evaluate low cortisone as a predictor of low renin activity and its association with parameters of kidney and vascular damage. Methods A cross-sectional study was carried out in 206 adult subjects. The subjects were classified according to low plasma renin activity (P < .001) and cortisone (r = 0.22; P = .001). A binary logistic regression analysis showed that serum cortisone per ug/dL increase predicted the low-renin phenotype (OR 0.4, 95% CI 0.21-0.78). The receiver operating characteristic curves for cortisone showed an area under the curve of 0.6 to discriminate subjects with low renin activity from controls. The low-cortisone subjects showed higher albuminuria and PAI-1 and lower sodium excretion. The association study also showed that urinary cortisone was correlated with blood pressure and serum potassium (P < .05). Conclusion This is the first study showing that low cortisone is a predictor of a low-renin condition. Low cortisone also predicted surrogate markers of vascular and renal damage. Since the aldosterone to renin ratio is used in the screening of PA, low cortisone values should be considered additionally to avoid false positives in the aldosterone–renin ratio calculation.


  • Clinical, biochemical, and miRNA profile of subjects with positive screening of primary aldosteronism and nonclassic apparent mineralocorticoid excess

    by Alejandra Tapia-Castillo, Cristian A. Carvajal, Jorge A. Pérez, Carlos E. Fardella

    Primary aldosteronism (PA) and nonclassic apparent mineralocorticoid excess (NCAME) have been recognized as endocrine-related conditions having a broad cli


  • Primary Aldosteronism, Aldosterone, and Extracellular Vesicles

    by Cristian A Carvajal, Alejandra Tapia-Castillo, Jorge A Pérez, Carlos E Fardella

    Primary aldosteronism (PA) is an endocrine related condition leading to arterial hypertension due to inappropriately high and unregulated aldosterone concentration. Recently, a broad spectrum of PA has been recognized, which brings new challenges associated with early identification of this condition that affect renal epithelial and extrarenal tissues. Reports have shown the potential role of extracellular vesicles (EVs) and EV cargo as novel and complementary biomarkers in diagnosis and prognosis of PA. In vivo and in vitro studies have identified specific EV surface antigens, EV-proteins, and EV microRNAs that can be useful to develop novel diagnostic algorithms to detect, confirm, or follow up the PA. Moreover, the study of EVs in the field of PA provides further insight in the pathophysiological mechanism of the PA disease.